When it comes to treating metastatic NSCLC tumors that lack gene fusions in the ALK and ROS genes or driving mutations in the EGFR gene, immunotherapy, either as monotherapy or in combination with chemotherapy, has solidified its place as the first line of treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.